依列卡福妥/替扎卡福妥/依伐卡托联合用药对囊性纤维化青少年葡萄糖耐量的短期影响——一项观察性初步研究
Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study.
作者信息
Korten Insa, Kieninger Elisabeth, Krueger Linn, Bullo Marina, Flück Christa E, Latzin Philipp, Casaulta Carmen, Boettcher Claudia
机构信息
Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Paediatric Endocrinology, Diabetology and Metabolism, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
出版信息
Front Pediatr. 2022 Apr 21;10:852551. doi: 10.3389/fped.2022.852551. eCollection 2022.
BACKGROUND
The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We performed an observational study on the short-term effects of ELX/TEZ/IVA on glucose tolerance.
METHODS
Sixteen adolescents with CF performed oral glucose tolerance tests (OGTT) before and 4-6 weeks after initiating ELX/TEZ/IVA therapy. A continuous glucose monitoring (CGM) system was used 3 days before until 7 days after starting ELX/TEZ/IVA treatment.
RESULTS
OGTT categories improved after initiating ELX/TEZ/IVA therapy ( = 0.02). Glucose levels of OGTT improved at 60, 90, and 120 min ( < 0.05), whereas fasting glucose and CGM measures did not change.
CONCLUSION
Shortly after initiating ELX/TEZ/IVA therapy, glucose tolerance measured by OGTT improved in people with CF. This pilot study indicates that ELX/TEZ/IVA treatment has beneficial effects on the endocrine pancreatic function and might prevent or at least postpone future CFRD.
背景
依列卡福/替扎卡福/艾伐卡福（ELX/TEZ/IVA）对糖耐量和/或囊性纤维化相关糖尿病（CFRD）的影响尚未完全明确。我们开展了一项关于ELX/TEZ/IVA对糖耐量短期影响的观察性研究。
方法
16名患有囊性纤维化（CF）的青少年在开始ELX/TEZ/IVA治疗前及治疗4 - 6周后进行了口服葡萄糖耐量试验（OGTT）。在开始ELX/TEZ/IVA治疗前3天至治疗后7天使用连续血糖监测（CGM）系统。
结果
开始ELX/TEZ/IVA治疗后OGTT类别有所改善（ = 0.02）。OGTT的血糖水平在60、90和120分钟时有所改善（ < 0.05），而空腹血糖和CGM测量值未发生变化。
结论
开始ELX/TEZ/IVA治疗后不久，CF患者通过OGTT测量的糖耐量有所改善。这项初步研究表明，ELX/TEZ/IVA治疗对胰腺内分泌功能有有益影响，可能预防或至少推迟未来的CFRD。
Zotero 插件